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Background: The Gab2 docking protein acts as an important signal amplifier downstream of various growth factor
receptors and Bcr-Abl, the driver of chronic myeloid leukaemia (CML). Despite the success of Bcr-Abl tyrosine kinase
inhibitors (TKI) in the therapy of CML, TKI-resistance remains an unsolved problem in the clinic. We have recently
shown that Gab2 signalling counteracts the efficacy of four distinct Bcr-Abl inhibitors. In the course of that project,
we noticed that two clinically relevant drugs, imatinib and dasatinib, provoke distinct alterations in the
electrophoretic mobility of Gab2, its signalling output and protein interactions. As the signalling potential of the
docking protein is highly modulated by its phosphorylation status, we set out to obtain more insights into the
impact of TKIs on Gab2 phosphorylation.
Findings: Using stable isotope labelling by amino acids in cell culture (SILAC)-based quantitative mass
spectrometry (MS), we show now that imatinib and dasatinib provoke distinct effects on the phosphorylation status
and interactome of Gab2. This study identifies several new phosphorylation sites on Gab2 and confirms many sites
previously known from other experimental systems. At equimolar concentrations, dasatinib is more effective in
preventing Gab2 tyrosine and serine/threonine phosphorylation than imatinib. It also affects the phosphorylation
status of more residues than imatinib. In addition, we also identify novel components of the Gab2 signalling
complex, such as casein kinases, stathmins and PIP1 as well as known interaction partners whose association with
Gab2 is disrupted by imatinib and/or dasatinib.
Conclusions: By using MS-based proteomics, we have identified new and confirmed known phosphorylation sites
and interaction partners of Gab2, which may play an important role in the regulation of this docking protein. Given
the growing importance of Gab2 in several tumour entities we expect that our results will help to understand the
complex regulation of Gab2 and how this docking protein can contribute to malignancy.
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Chronic myeloid leukaemia (CML) is characterized by
the increased and deregulated growth of myeloid cells in
the bone marrow and their accumulation in the peripheral
blood. CML represents about 20% of all cases of adult
leukaemia and has an incidence rate of 1.6 per 100,000
people per year. This form of leukaemia is staged into
three distinct phases. The first phase (chronic phase,
CP) is often asymptomatic and progresses over several
years to the accelerated phase (AP), if undiscovered or
left untreated. The AP ultimately progresses to the ter-
minal blast crisis (BC) which is characterized clinically
like an acute leukaemia. CML is driven by the oncogenic
Bcr-Abl tyrosine kinase. This kinase originates from the
spontaneous rearrangement of two human chromosomes
(Philadelphia chromosome) causing the production of a
chimeric protein with combined biological portfolios. The
Bcr-moiety recruits novel interaction partners, which are
modified on tyrosine residues with phosphate groups by
the Abl moiety, a typical protein tyrosine kinase. This in
turn activates numerous intracellular signalling pathways
that are, under physiological circumstances, only activated
by growth signals. As a result, cells, which harbour the
Philadelphia chromosome, grow excessively, even in the
absence of growth signals and thereby cause CML. This
insight led to the development of drugs inhibiting the
Bcr-Abl enzyme, which have revolutionised CML therapy.
In some patients, however, these drugs do not cause re-
mission or initially responsive leukaemia become drug
resistant. Among several mechanisms, dysregulation of
signal transducers downstream of Bcr-Abl, such as the
Gab2 docking protein, contribute to drug resistance.
In this manuscript, we provide a detailed analysis on
the phosphorylation status and protein interaction rep-
ertoire of Gab2 in CML cells in the presence and absence
of the clinically applied drugs imatinib (Gleevec) and
dasatinib (Sprycel).
Background
The oncogenic protein tyrosine kinase Bcr-Abl, the pro-
duct of the Philadelphia chromosome, drives chronic mye-
loid leukaemia (CML) [1]. This disease can be classified
into three distinct stages consisting of an often asympto-
matic chronic phase (CP), with less than 10% blasts in the
bone marrow, followed by an accelerated phase (AP) and
finally blast crisis (BC), with more than 20% blasts [2].
The latter phase resembles an acute leukaemia and is
usually fatal, if left untreated. The discovery of Bcr-Abl
and the subsequent elucidation of its structure and mode
of action led to the development of the tyrosine kinase
inhibitor (TKI) imatinib mesylate (IM) [3]. IM is an ATP-
competitive inhibitor and owes its success to the exploit-
ation of oncogene addiction, a phenomenon in which a
tumour cell has become critically dependent on a singleoncogenic pathway for its proliferation and/or survival
[4-6]. Consequently, inhibition of Bcr-Abl signalling pro-
vokes severe “withdrawal” symptoms and tumour regression.
Despite the useful application of IM in cancer therapy,
only 3 out of 4 CML cases respond adequately to IM in
the first place and several of the initially responding
tumours become TKI resistant due to the acquisition
of Bcr-Abl mutations preventing TKI uptake and/or action
[4]. This insight spurred the development of additional
Bcr-Abl inhibitors such as the ATP-competitive com-
pound dasatinib (DST). Bcr-Abl mutation-independent
mechanisms of TKI-resistance are also of clinical im-
portance, but remain ill-defined at the molecular level.
However, there is increasing evidence that the aberrant
activity or expression of components of the Bcr-Abl sig-
nalling network contribute to TKI-resistance [7,8]. Con-
sequently, the combination of Bcr-Abl inhibitors with
inhibitors of other signalling pathways may improve the
treatment of therapy-resistant CML [8,9]. Nevertheless,
such strategies will require an in-depth knowledge of
the individual components and their contribution to the
Bcr-Abl signalling network.
The fusion of the BCR and ABL reading frames extends
the portfolio of the Abl kinase by interaction partners of
the Bcr moiety such as the Grb2 adaptor [1,10]. As a con-
sequence, Bcr-Abl organises a multimeric protein complex
and activates various signalling pathways [11,12]. One
critical signal transducer of Bcr-Abl and Grb2 interaction
partner is the docking protein and proto-oncogene prod-
uct Gab2 [13,14]. Grb2 is connected via its central SH2
domain to phospho-tyrosine 177 (Y177) in the Bcr moiety,
while its C-terminal SH3 domain binds to a typical and an
atypical Grb2 binding site in Gab2 [10,15,16]. This “Grb2
bridge” is essential for the transformation of murine mye-
loid progenitors and for the prominent tyrosine phospho-
rylation of Gab2 in Bcr-Abl transformed cells [9,17].
These phospho-tyrosine residues act as docking sites for
various effectors with SH2 domains such as the tyrosine
phosphatase Shp2 and the regulatory p85 subunit of PI3K
[13]. The critical function of these residues was demon-
strated by the use of signalling-impaired Gab2 mutants in
which the phosphorylation of these docking sites was
prevented by blocking the Grb2/Gab2 interaction or by re-
placing the critical tyrosines by non-phosphorylatable
phenylalanine residues [9,17-20]. Upon Gab2 tyrosine
phosphorylation downstream effectors then mediate the
amplification of Bcr-Abl derived signals through the Ras/
ERK and PI3K/AKT/mTOR pathways. The activation of
these pathways can lead to uncontrolled proliferation and
survival in this and other settings, in which aberrant
Gab2 signalling contributes to tumourigenesis [9,13,14].
In addition to the relatively well-characterised tyrosine
phosphorylation sites, Gab2 is phosphorylated on more
than 20 Ser/Thr-residues, whose regulatory function
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(S159, S210, T391 and S623) fulfil important roles in
downregulating Gab2 signalling output by three distinct
negative feedback loops [19,21-23].
The important role of Gab2 downstream of Bcr-Abl is
illustrated by the observations that its genetic depletion
prevents the transformation of murine myeloid progeni-
tors by the fusion kinase [17] and slows down the proli-
feration of primary human CML cells and the CML cell
line K562 [9,24]. Furthermore, there is increasing evi-
dence that Gab2 expression levels or the abundance of
cells with prominent expression of the docking protein
increase during CML progression from chronic phase to
blast crisis [25,26]. Importantly, we have recently shown
in various CML model systems that Gab2 signalling con-
fers resistance to multiple Bcr-Abl selective TKIs [9]. In
this study, we demonstrated that IM and DST provoke
distinct alterations of the electrophoretic mobility and
signalling output of Gab2 suggesting that these drugs
impact differently on post-translational modifications, like
the phosphorylation status, of the docking protein. These
findings prompted us to conduct a more detailed character-
isation of the Gab2 signalling complex in response to the
TKIs IM and DST by quantitative mass spectrometry (MS).
Stable isotope labelling by amino acids in cell culture
(SILAC) is a metabolic labelling strategy allowing, amongst
other things the quantitative investigation of posttrans-
lational modification (PTM) [27], protein-protein interac-
tions [28], protein turnover [29] and organellar compositions
changes [30] by unbiased MS-based proteomics approaches.
Using SILAC-based MS, we show now on which sites and
to which extent both drugs affect the phosphorylation
status of Gab2. Additionally, we document the impact
of these drugs on the composition of Gab2-mediated
signalling complexes.
Results and discussion
In order to obtain more insights into the plasticity of
phosphorylation and protein interaction events in the Gab2
signalling complex in the context of Bcr-Abl signalling, we
made use of our previously established model systems, the
K562tet/Gab2-HA cell line and the murine pro-B cell line
Ba/F3 expressing p210Bcr-Abl ectopically [9]. K562tet/Gab2-
HA cells are derived from the K562 cell line, which was
established from a CML patient in blast crisis and is
widely used for the development of Bcr-Abl inhibitors
[31]. K562tet/Gab2-HA cells are fitted with an improved
doxycycline (dox)-inducible system for the expression of
haemagglutinin (HA)-tagged human Gab2 [9,32], which
can be efficiently purified for proteomic analyses [19].
Although overexpression of Gab2-HA may influence pro-
tein interactions, we only compare data generated in the
same isogenic cellular system. Hence, expression differ-
ences should not affect our findings.To gain more insights into the phosphorylation status
of Gab2 in Bcr-Abl positive cells, we first used phospho-
specific antibodies raised against phospho-tyrosine in gen-
eral (pY), pY452 (PI3K recruitment) and the PI3K dependent
feedback phosphorylation sites S159, S210 and T391 [19,21].
This analysis (Figure 1) showed that applications of the
two clinically relevant CML drugs, IM (1 μM) and DST
(0.01 and 1 μM), provoke distinct alterations in the elec-
trophoretic mobility of Gab2, a rough measure of its
phosphorylation status. The concentration of 1 μM IM
was chosen as it is in the range of the observed trough
plasma levels of CML patients receiving standard doses
of IM (1.76-2.95 μM; [33]) and is widely used to study
IM induced cell death in K562 cells [9,34,35]. Although
patients in chronic phase contain DST plasma levels
30-fold lower than the drug concentrations chosen for
our experiments, we decided to use also 1 μM DST as
we have previously shown that not all Gab2 amplified
signalling events, e.g. AKT phosphorylation, were abolished
by this concentration, and importantly, exogenous Gab2
was still able to protect K562 cells against 1 μM DST [9].
However, to account for the different IC50 values of the
two drugs, we also included a second DST concentra-
tion, 0.01 μM, which lies in the range of observed plasma
levels of DST, as well. The accelerated electrophoretic
mobility of Gab2 was accompanied by a drastic reduc-
tion in its overall tyrosine phosphorylation, while the
specific phosphorylation of Y452 was quite resilient in
K562 cells (Figure 1A) as reported previously [9]. Inter-
estingly, 0.01 μM DST, which exhibited a similar potency
in Bcr-Abl inhibition as 1 μM IM according to previous
findings [36] and our own data (compare the degree of
Bcr-Abl autophosphorylation at Y177 in Figure 1A be-
tween lanes 1 and 4), yielded a distinct pattern of overall
tyrosine phosphorylation than IM and was more potent in
reducing CrkL and ERK phosphorylation (Figure 1A).
Thus, despite equi-potent inhibition of Bcr-Abl, IM and
DST provoke distinct alterations of phosphorylation
events, which can be explained by the broader target
spectrum of the latter [37].
In agreement with our previous finding that both IM
and DST hardly block AKT phosphorylation in K562 cells
[9], we show here for the first time that S159 phosphor-
ylation is not abrogated by either the drugs. Likewise,
S210 and T391, which serve as binding sites for 14-3-3
proteins and whose phosphorylation is stimulated by
PI3K [19], display more or less constitutive phosphoryl-
ation (Figure 1A). While our work was in progress,
Preisinger et al. (2013) also reported that Gab2 is bound
to various 14-3-3 members under basal conditions and
that even a dose of 10 μM IM does not disrupt these
interactions [38]. Furthermore, a certain level of inhibi-
tory Gab2/14-3-3 complexes under steady state condi-




















































Figure 1 Inhibitor-dependent Gab2 phosphorylation. (A) K562tet cells stably transfected with the inducible Gab2wt expression vector or
‘empty’ control vector [9] were treated with 1 μg/ml dox for 24 h and then exposed to 1 μM imatinib or 0.01 μM and 1 μM dasatinib or to the
same volume of DMSO (vehicle control) for 4 h. Total cellular lysates were analysed by western blotting using the indicated antibodies. (B) The
murine proB cell line Ba/F3 was transduced with pBabe-Hygro-Bcr-Abl and subsequently with either pWZL-Bsr-Gab2-HA, or pWZL-Bsr empty
control vector [9]. Cells were exposed to either 1 μM imatinib or dasatinib or to the same volume of DMSO (vehicle control) for 1 h. Total cellular
lysates were analyzed by western blotting using the indicated antibodies.
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Gab2S210A/T391A double mutant (Gab22xA), which can-
not recruit 14-3-3 proteins [19], displays an enhanced
signalling potential in K562 cells [9]. Taken together,
even high doses of DST have minimal impact on the
three PI3K dependent phosphorylation sites on Gab2and its 14-3-3 binding potential. This is of particular
interest as a recent study, primarily conducted in HEK293
cells, provided convincing evidence that the ERK/RSK
axis can drive the phosphorylation of S159 and S210 as
well [39]. However, the fact that we still observe substan-
tial amounts of S159 and S210 phosphorylation despite
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contribution of the ERK pathway plays a minor role in
phosphorylation of these sites in K562 cells.
Moreover, the drastic increase in the electrophoretic
mobility of Gab2 in DST treated cells implies that many
more phosphorylation events are affected. Indeed, we had
shown previously that Gab2 is phosphorylated on more
than 20 Ser/Thr-residues in EGF-stimulated mammary
epithelial cells [19]. To conduct a quantitative direct com-
parison of Gab2 signalling complexes purified from IM or
DST treated cells, the K562tet/Gab2-HA line was subject
to a SILAC labelling protocol (Figure 2). The cells were
cultured with light (Arg0/Lys0), medium (Arg6/Lys4) and
heavy (Arg10/Lys8) labelled amino acids for ten days
and Gab2 overexpression was induced 24 h prior to the
treatment with 1 μM IM or DST (see Methods for details).
To exclude labelling artefacts, a biological replicate with
swapped labels was performed. In addition, a second
set of experiments was performed comparing 0.01 μM
to 1 μM DST to account for the different potencies of
IM and DST. Gab2 complexes were purified by immuno-
precipitation, pooled and analysed by MS. In addition to
the previously identified residues, we identified 18 novel
phosphorylation sites (Figure 3) raising the tally to 72 bona

















Figure 2 Quantitative proteomics workflow. Differentially SILAC labeled
and 1 μM dasatinib, and DMSO as control, respectively. Cells were lysed, Ga
eluted and combined 1:1:1 for further analysis. Proteins were separated by
mixtures analyzed by LC-MS/MS. A biological replicate with reversed labels
unspecific to beads and antibody will be present in a 1:1:1 ratio. Protein in
be reduced.from Y48/Y49, which were not identified in our studies,
none of the known phosphorylation sites maps to the PH
domain, but only to the very N-terminus and the long
disordered C-terminal tail (Figure 3). This observation
fits well to the notion that phosphorylation sites usually
occur within intrinsically disordered protein regions
[40,41]. It should be also noted that, in contrast to the
recent study by Preisinger et al. [38], we did not perform
an enrichment for phospho-tyrosine containing pep-
tides as this procedure could discriminate against Ser/
Thr-phosphorylated residues, which often represent the
outcome of negative feedback loops in tyrosine kinase
signalling [19,21-23,39]. The wealth of Gab2 phosphor-
ylation sites raises the question which kinases and phos-
phatases control these post-translational modifications
and identifies areas for future research. As indicated in
Figure 3 and in Additional file 1: Table S1, software
algorithms such as NetworKin [42] implicate several
kinases in these processes including CK2. In order to
provide a more comprehensive Gab2 phospho-map, we
combined our data with those of previous publications
and the curated Phosphosite database (Table 1). Inter-
estingly, this “meta-map” of Gab2 phosphorylation sites
(Table 1) reveals a largely isoform-specific cluster of









K562 cells were treated for 4 h with either 1 μM imatinib or 0.01 μM
b2 protein complexes purified by anti-HA sepharose, complexes
SDS-PAGE, in-gel digested using trypsin, and resulting peptide
was performed. Specific Gab2 interactors and proteins binding
teractions dependent on inhibitor sensitive phosphorylation sites will

































































































































































































































































































































































































































Figure 3 The Gab2 phosphomap in K562 cells. Shown is a representation of the Gab2 structure indicating domains, protein binding motifs
and sites. Phosphosites identified in this study are annotated in black, sites that respond more than two fold to imatinib and/or dasatinib in red.
Kinases known to phosphorylate a specific site are annotated in red, predicted kinases using NetworKIN [53] in black. * means PI3K dependent.
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to speculate that these phosphorylation events affect the
Gab2/Shp2 interaction as it was already discussed for
the single residues S623 [22] and S631 [39].
Using the SILAC-based quantification of the relative
abundances of phosphosites (Additional file 2: Table S2
and Additional file 3: Table S3), we next asked which
sites were altered in their relative phosphorylation status
by more than 2-fold, a common and conservative threshold
in phosphoproteomics studies, to discriminate responding
from non-responding sites [43], by either IM or DST
(Figure 4A-C and Additional file 4: Figure S1 C-E). We
observed that IM and DST at equimolar concentrations
suppressed the phosphorylation status of 9 sites and 20
sites, respectively. This is also reflected by the drastically re-
duced recognition of Gab2 by the pan-anti-phosphotyrosine
antibody 4G10 (Figure 1A). Interestingly, both inhibitors
provoke similar patterns, although in many cases more
prominent changes were observed with DST, while Gab2
sites from IM treated cells show only a trend in the same
direction (Figure 4A-C and Additional file 2: Table S2 and
Additional file 3: Table S3). This observation is in line with
the notion that DST is a more potent inhibitor than IM
[36] and that phosphorylation of Bcr-Abl at Y177 and CrkL,both widely used as read-outs and biomarkers for Bcr-Abl
inhibition [36], are more affected by DST, even at the lower
concentration of 0.01 μM (Figure 1A and Figure 5A).
Compared to IM, DST significantly affected the phosphor-
ylation status of S2, S132/133, S149, S281, Y491 and S634
of Gab2 at equimolar concentrations (Figure 4C). Interest-
ingly, our previous study in MCF-10A cells revealed that
the IM/DST sensitive sites in Gab2 S133, S149 and S281
are also EGF inducible, suggesting that these sites might
play a more general role in the regulation of Gab2. In
further agreement with our antibody-based analysis in
Figure 1, phosphorylation of T391 did not change sig-
nificantly in the current MS analysis. Taken together,
our data show that MS analyses mirror not only phos-
phorylation data obtained with antibodies, but allow the
rapid extension of phospho-maps to the many sites for
which antibodies are not available.
The stronger impact of DST on the overall phosphor-
ylation status of Gab2 is also reflected by its accelerated
electrophoretic mobility compared to the docking pro-
tein in lysates from IM or DMSO treated K562 and Bcr-
Abl-transformed Ba/F3 cells (Figure 1). However, given
the fact that DST targets a broader spectrum of kinases
than IM [37,44], including Src-family kinases that drive
Table 1 A meta-map of Gab2 phosphorylation









Y48 X X X
Y49 X X
S132 X
S133 X X X
S140 X X X
S141 X X X
S146 X
S148 X X X
S149 X X X
S159 Western
(Figure 1A)





S210 X X X 14-3-3 binding and negative
regulatory site [19,23]
S218 X X X X
S223 X X X
T225 X
Y249 X CrkL/PLCγ [13] X
S250 X X
S264 X X X X and phosphorylated [57]
T265 X X
Y266 X X CrkL/PLCγ [13] X
T278 X X
S281 X X X
T283 X
S285 X
T287 X X X
Y293 X X X CrkL [13] X
T294 X
T319 X X





T385 X X X
T391 X X X 14-3-3 binding and negative
regulatory site [19,23]
X and phosphorylated [57]
S404 X X X
S405 X X X X
T408 X
Y409 X X X
Y411 X
S422 X X and phosphorylated [57]
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Y452 X X p85 recruitment site;
Resilient against IM and





S480 X X X X
S488 X X X
Y491 X X
S506 X
S543 X X X ERK dependent phosphorylation
of the S543 equivalent critical
for PH-domain mediated
membrane recruitment of Gab1 [56].





Y584 X p85 [13] X
S611 X
Y614 X Shp2 [13] X
S622 X X X X
S623 X X X





T636 X X X
S637 X X
Y643 X X Shp2 [13] X
Comparison of the phospho-maps of Gab2 from this study with those established for IM treated K562 cells [38], EGF stimulated MCF-10A cells [19] and the sites
listed in the curated phosphosite database (www.phosphosite.org). Note that in addition to other entries, the entries from the MCF-10A cells are also represented
in this database. See Wöhrle et al. (2009) for further details on the indicated docking sites. Gab2 phoshorylation sites that have a homotopic counterpart in Gab1
(incl. conserved S⇔T conversions) were identified by comparing the human Gab2 (NP_53679) and Gab1 (NP_997006.1) sequences using the BLASTP 2.2.27+ tool.
However, it should be noted that in many cases only the phosphorylation site itself and not its context were conserved between both paralogues, like it was
described for the T391/T387 in Gab2/Gab1 [19,57]. All new Gab2 phosphorylation sites, identified in this study were marked in bold.
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it is still surprising that the patterns are quite similar.
In full agreement with our previous study [9] and the
data in Figure 1, we observe also by MS that IM does
not affect one of the three PI3K recruitment sites, pY452,
while DST leads to a modest reduction (44%) of this
phosphorylation site in K562 cells (Additional file 2:
Table S2 and Additional file 3: Table S3). This finding is
in line with the observation that both inhibitors do not
block Gab2-enhanced AKT phosphorylation in K562 cells
(Figure 5A), an event that we previously correlated withTKI resistance in K562 cells and primary CML cells [9].
In contrast to these findings, we also observed a drastic
reduction in the interaction of Gab2 to the p85α/β sub-
units (PIK3R1/2) (Figure 6A, C, E, H and Additional file 5:
Table S4), suggesting a stronger influence of IM and DST
on the other two PI3K recruitment sites (Y476 and Y584),
which we were not able to detect in our MS analysis.
For one of the two Shp2 recruitment sites Y643, both
drugs reduced the phosphorylation by more than 80%
(Additional file 3: Table S3), which could explain their
efficacy to block Gab2 enhanced ERK phosphorylation






























































































Figure 4 The phosphorylation status of Gab2 is differentially affected by imatinib and dasatinib. (A-B) Plotted are Gab2 phosphosite
ratios normalized to Gab2 protein ratios of imatinib, dasatinib versus control treated cells of two biological replicates against respective summed
peptide intensities. Sites changing more than two fold are annotated and marked in red. (C) Same set-up as for (A-B) except that Gab2
phosphosites from imatinib treated cells are compared with those from dasatinib treated cells.
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Figure 5A and B).
Finally, we used our SILAC data to compare the
spectrum of Gab2 interaction partners in IM or DST
treated cells (Additional file 5: Table S4). Protein SILAC
ratios were normalized to Gab2 levels, log2 transformed,
and ratios of two biological replicates, each, were plotted
against each other. Significant outliers in minimally one
of the treatments, showing decreased interaction with
Gab2 upon treatment, were identified by assuming a normal
distribution and calculating Benjamini-Hochberg corrected
p values (p < 0.05) using the significance B value of the
MaxQuant software [46]. From the identified 1,047 pro-
teins, 18 exhibited similarly reduced interactions in
both treatments, 3 reacted stronger in DST treated and
6 in IM treated cells, respectively (Figure 6A and B and
Additional file 4: Figure S1A and B). As an internal
control, we show that peptides annotated to the Bcr
and Abl proteins co-cluster in our graph as they are
generated by proteolysis in equimolar proportions fromthe same Bcr-Abl peptide chain (Figure 6B). We observed
a greater loss of Bcr-Abl from Gab2 signalling complexes
in cells treated with 1 μM DST compared to cells treated
with 0.01 μM DST or IM (Figure 6B-D and H), which
might be partially explained by the residual phosphoryl-
ation of Bcr-Abl at the Grb2 binding site Y177 in IM com-
pared to DST treated cells. In contrast, the interactions
of Gab2 with the seven detected 14-3-3 proteins appear
to be largely unresponsive to inhibitor treatments exhibiting
no significant alterations (Figure 6G) as also indicated
by the stable phosphorylation of S210 and T391 in TKI
treated cells (Figure 1).
As shown in Figure 6A and C, IM and DST cause only
a modest but significant reduction in the Grb2/Gab2
interaction, which fits well to the observation that this
protein-protein interaction is mediated by a SH3 domain
and is not supposed to be directly affected by changes
in the Gab2 phosphorylation status [15]. However, the
fact that the Grb2/Gab2 interaction is still affected by





























1 1 1 µM
BA
Figure 5 Inhibitor-dependent effects on Bcr-Abl and Gab2 downstream effectors. (A) K562tet cells stably transfected with the inducible
Gab2wt expression vector or ‘empty’ control vector [9] were treated with 1 μg/ml dox for 24 h and then exposed to either 1 μM imatinib or
dasatinib or to the same volume of DMSO (vehicle control) for 4 h. Total cellular lysates were analyzed by Western blotting using the indicated
antibodies. (B) The murine proB cell line Ba/F3 was transduced with pBabe-Hygro-Bcr-Abl and subsequently with either pWZL-Bsr-Gab2-HA, or
pWZL-Bsr empty control vector [9]. Cells were exposed to either 1 μM imatinib or dasatinib or to the same volume of DMSO (vehicle control) for
1 h. Total cellular lysates were analyzed by Western blotting using the indicated antibodies. Please note that the Western blot B from this Figure
and the one from Figure 1B belong to the same experiments and that the Gab2 and β-Actin panels are shown on both Figures.
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C-terminal tails of Gab docking proteins is dynamically
regulated by phosphorylation events [41,47].
The adaptor proteins SHC1 and SHC2 bind to Gab2
either directly via their SH2 domain, or, what has been
more consistently observed in several systems, indirectly
via Grb2 (see [13] for discussion and additional refer-
ences). However, both potential interaction modes require
phosphotyrosine-dependent interactions and therefore the
drastic reduction of both SHC proteins in IM and DST
treated cells validates our approach (Figure 6A). The role
of SHC proteins in Gab signalling complexes remains
still unclear, although there is accumulating evidence
from other experimental systems that they contribute to
the recruitment of the lipid phosphatases SHIP1 and
SHIP2 to Gab docking proteins [13]. Indeed, we observe a
depletion of SHIP2 (INPPL1) to a similar extent as the
SHC proteins in Gab2 signalling complexes purified from
IM and DST treated cells (Figure 6A). This finding con-
firms an earlier study showing that SHIP2 is constitutively
phosphorylated and SHC-associated in K562 cells [48].
Furthermore, both TKIs induce a significant reduction
of known direct Gab2 interaction partners such as Shp2(PTPN11) and the p85α/β subunits (PIK3R1/2) as it was
also recently described for IM treated K562 cells [38].
Commensurate with the loss of the latter, we noticed a
reduction of the catalytic PI3K subunit, p110α, encoded
by PIK3CB. Interestingly, p110α and both p85 subunits
cluster close to each other (Figure 6A, E, and H), suggesting
that they leave the Gab2 signalling complex to a similar
extent. We also observe that both TKIs lead to a signifi-
cant reduction of the Crk adaptor in Gab2 signalling
complexes, which is a direct interaction partner of both
Bcr-Abl (via its SH3 domain) and Gab2 (via its SH2
domain; see [13,49] for further details and references).
Interestingly, CrkL, which represents the preferred bind-
ing partner and substrate of Bcr-Abl [50], was present
but not significantly decreased in Gab2 complexes purified
from either IM or DST treated cells (Additional file 5:
Table S4). This finding suggests that CrkL is predomin-
antly bound by Bcr-Abl in a phosphotyrosine independent
manner and might be of interest in the light of CrkL as a
commonly used predictive marker for TKI-responsiveness
in CML patients [50].
Our analysis also identifies several proteins as significantly
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Figure 6 (See legend on next page.)
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Figure 6 Imatinib and dasatinib sensitive Gab2 protein interactions. Scatter plot of proteins showing significant change in the interaction
with Gab2 with either (A) similar or (B) different responses to the imatinib and dasatinib treatments. (C) Network diagram of protein-protein
interactions of the identified Gab2 interactors. Blue nodes indicate proteins with a similar response to the treatments, green and red nodes are
proteins that dissociate stronger in response to Dasatinib or Imatinib, respectively. Red edges indicate protein-protein interactions present in the
STRING database (score >0.7) and blue edges indicate putatively novel interactions. Barplot of the observed ratios for (D) Bcr-Abl, (E) PI3 kinases,
(F) Casein kinases and (G) 14-3-3 protein isoforms, error bars indicate standard deviation of the two biological replicates. (H) Significantly depleted
proteins highlighted in panels (A and B) are tested on their sensitivity to different dasatinib concentrations (0.01 and 1 μM).
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Although protein abundance differences due to the 4 h
of TKI treatment may influence our findings in certain
cases, we still regard most interactions as specific due
to repeated significant alterations. The first novel TKI-
sensitive interaction partners are Stathmin 1 and 2, im-
portant regulators of microtubule dynamics. The second
represents PIP1, an aspartyl protease. Although PIP1 has
been linked by several reports to breast cancer progres-
sion, it remains still enigmatic in terms of its precise
biological function [51]. Furthermore, its expression in
multiple exocrine glandular epithelia, its presence in
several bodily fluids and its action on extracellular matrix
proteins raises the concern whether the association with
Gab2 represents a post-lysis artefact. Nevertheless, this
protein has been found to interact with the C-terminus
of aquaporin 5 suggesting a potential cytoplasmic local-
isation [52]. Furthermore, we found PIP1 associated with
Gab2 in MCF-10A cells (F.U.W., Adrian Sprenger, J.D
and T.B. unpublished data). Future studies will be needed
to further validate this interaction. In any case, the detec-
tion of PIP1 represents the first report of its expression
in CML cells.
We also observe a decrease of the Casein kinase I α
(CSNK1A1; CK1) and Casein kinase II α’ (CSNK2A2;
CK2) subunits (Figure 6A, C and F), both representing
novel interaction partners of Gab2. CK1 and CK2 encode
the catalytic subunits of their respective holoenzymes
and represent, despite their similar names, members of
two different Ser/Thr-kinase subfamilies with distinct
consensus phosphorylation sites [53]. Of note, we iden-
tified CK2 as a potential kinase being responsible for
the phosphorylation of several sites detected in this
study (Figure 3). In addition, CK2 is increasingly implicated
as a critical oncogenic kinase in several hematopoietic
malignancies and solid tumours as well as an activator
of the JAK/STAT signalling pathway [54]. Thus, the
TKI-sensitive interaction between the Gab2 and CK2
oncoproteins invites for further analyses.
Conclusions
In summary, our comparative analysis shows that the
distinct efficacies of IM and DST are reflected by the
differentially altered overall phosphorylation status of
the Gab2 protein. Our analysis further underscores thatlarge docking proteins with their extended disordered
regions are very rich in phosphorylation sites, whose
functions are just starting to emerge [13,41,47,55]. This
notion is further supported by recent phospho-proteomic
analyses of other large docking proteins such as Gab1
[56,57] or SLP-65/BLNK [58]. Thus, MS-based proteomics
represents an ideal method to quantify the complex
spatio-temporal phosphorylation patterns of large docking
proteins. These detailed phosphorylation catalogues, which
are generated by focussing on single protein complexes
and are therefore more comprehensive in terms of data
depth than global approaches, are also of growing rele-
vance. Indeed, we and others could recently show that
disease associated mutations in phosphorylation sites
or of critical residues constituting their recognition by
cognate kinases are found in various signalling mole-
cules, including several docking protein family members
[57,59,60]. Furthermore, MS provides a valuable tool to
gain insight into the influence of TKIs on the composition
of Gab2 signalling complexes. Given the growing import-
ance of Gab2 in several tumour entities [13,14], we expect
that our approach and results will help to shed more light
on the various mechanisms by which this docking protein
contributes to malignancy.
Methods
Transfection and infection of cell lines
Plat-E cells were cultured as described previously [19,61]
and transfected using polyethylenimine (Polysciences).
Ba/F3 cells were infected with Plat-E culture super-
natant as described previously [18]. For the generation
of K562/tet cells and their derivatives, 2 × 107 cells were
electroporated with 30 μg FspI-linearized plasmid DNA.
Selection of Ba/F3 and K562 cells was commenced 24 h
post infection/electroporation (hygromycin B: 0.5 mg/ml,
Calbiochem; blasticidin S: 5 μg/ml, Roth; puromycin:
5–7 μg/ml, Sigma).
Expression vectors
The retroviral pBabe/Bcr-Abl-Hygro vector was derived
from pMIG/p210Bcr-Abl, a kind gift from Dr. Sebastian
Herzog, Albert-Ludwigs-University, Freiburg (Germany).
The Bcr-Abl cDNA was excised from pMIG/p210Bcr-Abl
using EcoRI and subcloned into the EcoRI-linearized pBabe-
Hygro expression vector. To generate the expression
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by PCR from the retroviral pMIG-hGab2-HA [18] and
then subcloned into pWZL-Bsr (Addgene). The expres-
sion vectors for dox inducible expression of Gab2 in
K562tet cells have been described in detail elsewhere
[9,32]. Detailed cloning procedures, as well as plasmid
sequences, are available upon request.
Western blotting
K562 and Ba/F3 cells were processed to total cellular lysates
by lysing in normal lysis buffer (50 mM TRIS/HCL pH 7.4,
1% Triton-X 100, 137 mM NaCl, 1% Glycerin, 1 mM
Natrium Orthovanadate, 0.1 μg/μl Aprotine, 0.01 μg/μl
leupeptin, 1mM AEBSF) and analyzed by western blot-
ting as described previously [18].
SILAC labeling of K562 cells
K562 cells expressing Gab2-HA were cultured in DMEM
(Pan Biotech, Aidenbach, Germany) containing 4.5 g/l glu-
cose, Na-Pyruvat, 3.7 g/l NaHCO3, supplemented with
penicillin/streptomycin (100 U/ml, 100 μg/ml), glutamine,
10% fetal calf serum (PAA, Coelbe, Germany). Cell popu-
lations were labeled for 6 cell doublings with either “light”
AA: L-arginine and L-lysine (Arg0, Lys0, Sigma Aldrich),
or “medium” AA: L-arginine-13C6-
14N4 (Arg6; Sigma-
Aldrich, Taufkirchen, Germany) and L-lysine-2H4 (Lys4;
Silantes, Munich, Germany), or “heavy” AA: L-arginine-13C6-
15N4 (Arg10; Sigma-Aldrich) and L-lysine-
13C6-
15N2
(Lys8; Silantes) in SILAC-DMEM media (Thermo Fisher,
Langenselbold, Germany), supplemented with L-proline,
penicillin/streptomycin (100 U/ml, 100 μg/ml), glutamine,
and 10% dialyzed fetal calf serum (Gibco, Paisley, UK)
which was used during labeling.
MS sample preparation
SILAC labelled cells were lysed with normal lysis buffer
(50 mM TRIS/HCL pH 7.4, 1% Triton-X 100, 137 mM
NaCl, 1% Glycerin, 1 mM Natrium Orthovanadate,
0.1 μg/μl Aprotine, 0.01 μg/μl leupeptin, 1 mM AEBSF),
cell nuclei were pelleted and supernatants were used for
affinity purification. Gab-HA complexes were enriched
using anti-HA-sepharose (Roche Applied Science) in sep-
arate IPs, one IP per SILAC label. In the last washing step,
sepharose beads were combined and protein complexes
eluted by incubating beads for 10 min at 95°C in SDS
loading buffer containing 1 mM DTT (Sigma-Aldrich).
Reduced samples were alkylated using iodoacetamide
(5.5 mM) (Sigma-Aldrich). Protein mixtures were sepa-
rated by SDS-PAGE (4-12% Bis-Tris gradient gel,
NuPAGE (Invitrogen, Karlsruhe, Germany)), gel lanes
were cut into 10 slices according to their protein con-
tent, samples in-gel digested using trypsin (Promega,
Mannheim, Germany), and resulting peptide mixtures
were STAGE tipped.LC-MS/MS and data processing
Samples for LC-MS/MS were fractionated by nanoscale–
HPLC on either an Agilent 1200 or an Eksigent NanoLC-
ultra connected online to a LTQ-Orbitrap XL (Thermo
Scientific). Peptides were separated over a linear gradient
from 10-30% ACN in 0.5% acetic acid with a flow rate of
250 nl/min. All full-scan acquisition was done in the
FT-MS part of the mass spectrometers in the range
from m/z 350–2000 with an automatic gain control tar-
get value of 106 and at resolution 60,000 at m/z 400. MS
acquisition was done in data-dependent mode to se-
quentially perform MS/MS on the five most intense ions
in the full scan (Top5) in the LTQ using the following
parameters. AGC target value: 5,000. Ion selection thresh-
olds: 1000 counts and a maximum fill time of 100 ms.
Wide-band activation was enabled with an activation
q = 0.25 applied for 30 ms at a normalized collision
energy of 35%. Singly charged and ions with unassigned
charge state were excluded from MS/MS. Dynamic exclu-
sion was applied to reject ions from repeated MS/MS
selection for 45 s.
All recorded LC-MS/MS raw files (40) were processed
together in MaxQuant [46] version 1.3.0.2 with default
parameters using the June 2012 UniProt human data-
base which contains 86,898 protein sequences. For
databases searching parameters were mass accuracy
thresholds of 0.5 (MS/MS) and 20 ppm (precursor),
Trypsin/P+DP asprotease, maximum three missed cleav-
ages, carbamidomethylation (C) as fixed modification
and oxidation (M), phosphorylation (STY) and protein
N-terminal acetylation as variable modifications. MaxQuant
was used to filter the identifications for a FDR below 1%
for peptides, sites and proteins using forward-decoy
searching. Match between runs were enabled with a
retention time window of 2 min.
Phosphosites with localization probabilities ≥0.75 (class I
sites) were used for bioinformatics analyses.
Reagents and inhibitors
Imatinib mesylate and dasatinib were purchased from
Santa Cruz Biotechnology. Doxycycline hyclate was obtained
from Sigma Aldrich. Anti-HA Affinity Matrix was pur-
chased from Roche.
List of antibodies
Antibodies used in this study were: anti-c-Abl (sc-131),
anti-β-Actin (sc-47778) and anti α-Tubulin (sc-23948), all
from Santa Cruz, anti-phospho-AKT S473 and T308, anti-
p44/p42 MAP kinase, anti-phospho-p44/p42 MAP kinase
T202/Y204, anti-phospho-Bcr Y177, anti-Gab2 (26B6),
anti-phospho-Gab2 Y452 (C33G1) and S159, anti-CRKL,
anti-phospho-CRKL and anti-phospho-STAT5 all from
Cell Signaling Technology, anti-HA (3F10) from Roche
Molecular Bioscience, anti-phospho-tyrosine (4G10) from
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bodies were described previously [19] and obtained from
Symansis.
Additional files
Additional file 1: Table S1. Kinase predictions from NetworKin. Amino
acid sequences surrounding phosphorylation sites were employed to
predict potential kinases responsible for phosphorylation using the
NetworKIN algorithm.
Additional file 2: Table S2. Gab2 phosphorylation, imatinib and
dastanib compared to DMSO treatment. Phosphosite identification and
quantification information is shown. SILAC Gab2 phosphosite ratios of IM
and DST treated cells compared to DMSO treated controls are depicted.
Additional file 3: Table S3. Gab2 phosphorylation, dastanib compared
to imatinib treatment. Phosphosite identification and quantification
information is shown. SILAC Gab2 phosphosite ratios of DST treated cells
compared to IM treated cells are depicted.
Additional file 4: Figure S1. Correlation of protein purification and
quantification of biological replicates. (A-B) Correlation of protein
quantifications of biological replicates for (A) imatinib treated cells versus
DMSO treated controls and (B) dasatinib treated cells versus DMSO
treated controls. Significant depleted proteins are annotated in red (sign.
B, p < 0.05 BH corrected). (C-E) Correlation of phosphosite quantification.
Plotted are Gab2 phosphosite ratios normalized to Gab2 protein ratios of
(C) imatinib versus control, (D) dasatinib versus control, and (E) dasatinib
versus imatinib treated cells of two biological replicates.
Additional file 5: Table S5. Gab2 protein-protein interactions, imatinib
and dastanib compared to DMSO treatment. Protein identification and
quantification information is shown. SILAC ratios of proteins identified in
Gab2-HA immuno-precipitations of IM (1 μM) and DST (0.01 μM and 1 μM)
treated versus DMSO treated cells are depicted. Proteins exhibiting inhibitor
sensitive interactions are highlighted (p<0.05, BH corrected).
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